{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060589","form_type":"8-K","ticker":"INGN","cik":"0001294133","company_name":"Inogen Inc","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.754435+00:00","generated_at":"2026-06-01T22:45:36.634351+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Inogen CMO Stanislav Glezer departs; severance includes 12-month salary & COBRA","bullets":["Dr. Stanislav Glezer separated as EVP R&D and Chief Medical Officer effective April 11, 2024.","Severance: 12 months base salary of $505,000 (26 pay periods) and COBRA premium reimbursement for 12 months.","Unvested equity awards forfeited; vested stock options remain exercisable per plan terms.","No annual bonus owed; tuition repayment for CEO program waived.","Separation agreement includes standard release of claims and confidentiality obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060589","json":"https://secwatch.observer/filing/0000950170-24-060589.json","markdown":"https://secwatch.observer/filing/0000950170-24-060589.md","text":"https://secwatch.observer/filing/0000950170-24-060589.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024060589/0000950170-24-060589-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024060589/ingn-20240510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:45:36.634351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f843f5c293","claim":"Stanislav Glezer departed as Executive Vice President, R&D and Chief Medical Officer at Inogen Inc.","evidence_excerpt":"Dr. Glezer’s role as an officer and employee of the Company ended effective April 11, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1294133/000095017024060589/0000950170-24-060589-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Executive Vice President, R&D and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}